CR treatment effect of tisagenlecleucel vs blinatumomab
| Method . | OR . | 95% CI . | P . |
|---|---|---|---|
| Unadjusted OR | |||
| Univariate logistic regression | 8.09 | 3.76-17.38 | <.0001 |
| Marginal OR | |||
| Logistic regression with sIPTW | 7.80 | 3.66-16.60 | <.0001 |
| Logistic regression with trimmed sIPTW | 7.49 | 3.52-15.96 | <.0001 |
| Conditional OR (adjusted) | |||
| Logistic regression stratified by quintiles of propensity score | 6.71 | 3.06-14.71 | <.0001 |
| Logistic regression adjusting for prognostic factors | 9.76 | 4.09-23.28 | <.0001 |
| Logistic regression adjusting for prognostic factors and propensity score | 9.71 | 4.03-23.40 | <.0001 |
| Method . | OR . | 95% CI . | P . |
|---|---|---|---|
| Unadjusted OR | |||
| Univariate logistic regression | 8.09 | 3.76-17.38 | <.0001 |
| Marginal OR | |||
| Logistic regression with sIPTW | 7.80 | 3.66-16.60 | <.0001 |
| Logistic regression with trimmed sIPTW | 7.49 | 3.52-15.96 | <.0001 |
| Conditional OR (adjusted) | |||
| Logistic regression stratified by quintiles of propensity score | 6.71 | 3.06-14.71 | <.0001 |
| Logistic regression adjusting for prognostic factors | 9.76 | 4.09-23.28 | <.0001 |
| Logistic regression adjusting for prognostic factors and propensity score | 9.71 | 4.03-23.40 | <.0001 |
OR is the odds ratio of tisagenlecleucel vs blinatumomab. An OR >1 indicates that tisagenlecleucel is associated with a higher odds of response than blinatumomab.